Preprint Suggests, Vir-GSK's COVID-19 Antibody Can Evade Omicron Sub-Variant

In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc GSKVir Biotechnology Inc VIR and Eli Lilly And Co's LLY COVID-19 treatments.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 Coronaviruswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!